ÅH

Åsa Holmgren

Head of Regulatory Affairs

Therapeutic Areas

Drug	Indication	Phase
ONC175 (synthetic orellanine)	Metastatic Clear-Cell or Papillary Renal Cell Carcinoma (initially in patients on dialysis)	Phase 1/2